CardioExchange Archive

March 13th, 2014

Achieving Consensus for the 2014 ACC/AHA Valvular Heart Disease Guideline

Catherine M. Otto, MD and Rick Akira Nishimura, MD

The writing committee co-chairs of the 2014 ACC/AHA Valvular Heart Disease Guideline discuss how the committee achieved consensus on the future treatment of valvular disease.

---

March 3rd, 2014

New Guidelines Issued for Valvular Heart Disease

Larry Husten, PHD

The American Heart Association and the American College of Cardiology today released new practice guidelines for the management of patients with valvular heart disease (VHD). Among its most notable features, the new document provides a new system of classification for VHD and lowers the threshold for interventions, including, for the first time, transcatheter as well […]

---

January 20th, 2014

FDA Grants Earlier Than Expected Approval for Medtronic’s CoreValve

Larry Husten, PHD

The FDA today approved Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are unable to undergo conventional open-heart surgery. The approval came several months ahead of expectations and without an FDA advisory panel meeting. The approval was based largely on results from the Extreme Risk Study of the CoreValve […]

---

December 3rd, 2013

Estimating Prosthesis-Patient Mismatch for Patients Undergoing Bovine Pericardial AVR

Jyothy Puthumana, MD,MS

Jyothy Puthumana discusses his research group’s Circulation: Cardiovascular Imaging study, for which they compared prosthesis-patient mismatch prevalence and its impact on survival.

---

September 23rd, 2013

Using Registry Data, FDA Expands Indication for Edwards’ Sapien Transcatheter Heart Valves

Larry Husten, PHD

Relying on an important new source of information, the FDA said today that it had expanded the label for the Sapien Transcatheter Heart Valve (Edwards Lifesciences). Previously, the Sapien was approved for insertion via the transfemoral or transapical access points in patients not eligible for traditional aortic valve surgery. The new labeling no longer mentions access points […]

---

July 15th, 2013

The Conundrum of Low-Gradient Severe Aortic Stenosis with Preserved LVEF

Thomas Marwick and John Ryan, MD

Thomas Marwick discusses his research group’s study of how patients who have severe aortic stenosis with low gradient and a preserved LV ejection fraction fare after aortic valve replacement.

---

July 12th, 2013

Medtronic Faces Removal of CoreValve Transcatheter Heart Valve from German Market

Larry Husten, PHD

In the wake of a major patent decision, Medtronic will be forced to remove its CoreValve transcatheter heart valve from the German market. Edwards Lifesciences said today that a German Court had found that Medtronic infringed a key patent, known as the Spenser patent, and granted an injunction prohibiting the sale of CoreValve and CoreValve Evolut systems in Germany. Medtronic said it would appeal the […]

---

February 20th, 2013

Small Study Explores Expanded Use for TAVI in Native Valve Aortic Regurgitation

Larry Husten, PHD

As transcatheter aortic valve implantation (TAVI) gains increasing acceptance, cardiologists and surgeons are exploring additional patient populations who may benefit from the procedure. A new paper in the Journal of the American College of Cardiology provides the first look at the use of TAVI in the small but important group of patients with pure, severe native aortic […]

---

November 27th, 2012

Longer Warfarin Therapy After Bioprosthetic Aortic Valve Replacement May Be Beneficial

Larry Husten, PHD

Three months of warfarin is the usual standard of care following bioprosthetic aortic valve replacement (AVR),  although the supporting evidence base for this practice is limited. A new, large registry study published in JAMA suggests that more-prolonged warfarin therapy may be beneficial. Danish researchers identified 4075 patients who underwent bioprosthetic AVR. As expected, warfarin treatment between 30 and […]

---

October 24th, 2012

TCT: Impressive Survival Benefit for TAVR in Inoperable Patients at 3 Years

Larry Husten, PHD

At the TCT meeting in Miami, Murat Tuzcu presented the latest findings from the PARTNER B trial comparing transcatheter aortic valve replacement (TAVR) with standard therapy in patients who are not considered eligible for surgical valve replacement. At 3 years, the mortality advantage continued to grow for TAVR over standard therapy. All-cause mortality at 3 years: 80.9% […]

---